All In Biotech

Drug Trial Radar · NCT06904105

A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 Tablets in Subjects With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 556 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

556

Actual

Start

Apr 10, 2025

Primary completion

Apr 17, 2026

Study completion Jun 12, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.

Conditions

  • Overweight
  • Obesity

Interventions

  • HRS-7535 TabletsDrug

    HRS-7535 tablets.

  • HRS-7535 Placebo TabletsDrug

    HRS-7535 placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight relative to the baselineTime frame: 44th week after administration.
  2. Proportion of participants with a body weight reduction of ≥ 5% relative to the baselineTime frame: 44th week after administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.